SCHEMBL1745440

SCHEMBL1745440

COC(=O)CCc1ccc(OC2CCc3cc(-c4ccccc4)ccc32)cc1

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GFRA3 O60609 4/20 0.48
RET P07949 1/20 0.48
HCAR2 Q8TDS4 2/20 0.46
FFAR1 O14842 10/20 0.46
HRH3 Q9Y5N1 1/20 0.43
AKR1B1 P15121 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
PPARD Q03181 1/20 0.41
GFRA2 O00451 2/20 0.41
CTSD P07339 1/20 0.41
GFRA1 P56159 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1747100 0.93 FFAR1 (0.45) GFRA3RETHCAR2FFAR1HRH3
SCHEMBL1747068 0.92 FFAR1 (0.43) GFRA3RETHCAR2FFAR1HRH3
SCHEMBL1744691 0.91 HRH3 (0.42) GFRA3RETHCAR2FFAR1HRH3
SCHEMBL1746658 0.91 FFAR4 (0.46) GFRA3RETHCAR2FFAR1HRH3
SCHEMBL1744798 0.89 FFAR1 (0.53) GFRA3RETFFAR1AKR1B1FFAR4
SCHEMBL1744736 0.88 FFAR1 (0.44) GFRA3RETFFAR1FFAR4PPARD
SCHEMBL1747248 0.86 GRIN2B (0.44) FFAR1PPARD
SCHEMBL1744689 0.86 FFAR1 (0.46) GFRA3RETFFAR1PPARD
SCHEMBL1744612 0.86 FFAR1 (0.48) FFAR1FFAR4
SCHEMBL1744692 0.86 FFAR1 (0.52) GFRA3FFAR1HRH3GFRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR GFRA3 412/4885RET 528/4885HCAR2 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.